Content
04/23/2024
Cambridge, MA USA
Red Arrow Therapeutics
completed $4.5 million Seed Round funding. Investors include
Beyond Next Ventures, Keio Innovation Initiative, Osaka University Venture Capital, The University of Tokyo Edge Capital Partners.
About
Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy.
In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
